A 2-week polysomnographic safety study of sodium oxybate in obstructive sleep apnea syndrome

摘要

PurposeSodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects ∼9–50% of narcoleptics. Effects of 2-week SXB administration on apnea–hypopnea index (AHI), oxygen saturation (SaO2), and sleep architecture were investigated in OSAS patients.